BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise

After a long and challenging journey for its stem cell therapy NurOwn, BrainStorm Cell Therapeutics has aligned with the FDA on the parameters of a Phase IIIb ALS trial that is expected to begin by the end of 2024.